全文获取类型
收费全文 | 12160篇 |
免费 | 705篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 153篇 |
儿科学 | 680篇 |
妇产科学 | 191篇 |
基础医学 | 1249篇 |
口腔科学 | 300篇 |
临床医学 | 854篇 |
内科学 | 2824篇 |
皮肤病学 | 248篇 |
神经病学 | 722篇 |
特种医学 | 465篇 |
外国民族医学 | 1篇 |
外科学 | 1932篇 |
综合类 | 347篇 |
一般理论 | 9篇 |
预防医学 | 734篇 |
眼科学 | 373篇 |
药学 | 932篇 |
中国医学 | 51篇 |
肿瘤学 | 845篇 |
出版年
2023年 | 93篇 |
2022年 | 63篇 |
2021年 | 363篇 |
2020年 | 244篇 |
2019年 | 301篇 |
2018年 | 389篇 |
2017年 | 287篇 |
2016年 | 313篇 |
2015年 | 350篇 |
2014年 | 480篇 |
2013年 | 629篇 |
2012年 | 859篇 |
2011年 | 904篇 |
2010年 | 585篇 |
2009年 | 426篇 |
2008年 | 696篇 |
2007年 | 742篇 |
2006年 | 654篇 |
2005年 | 614篇 |
2004年 | 514篇 |
2003年 | 443篇 |
2002年 | 408篇 |
2001年 | 234篇 |
2000年 | 239篇 |
1999年 | 204篇 |
1998年 | 101篇 |
1997年 | 66篇 |
1996年 | 64篇 |
1995年 | 73篇 |
1994年 | 59篇 |
1993年 | 38篇 |
1992年 | 114篇 |
1991年 | 108篇 |
1990年 | 93篇 |
1989年 | 121篇 |
1988年 | 96篇 |
1987年 | 88篇 |
1986年 | 67篇 |
1985年 | 78篇 |
1984年 | 68篇 |
1983年 | 61篇 |
1982年 | 37篇 |
1979年 | 49篇 |
1978年 | 33篇 |
1976年 | 32篇 |
1975年 | 31篇 |
1974年 | 39篇 |
1973年 | 39篇 |
1972年 | 30篇 |
1969年 | 35篇 |
排序方式: 共有10000条查询结果,搜索用时 37 毫秒
1.
2.
Syed M. Gilani Muhammad Khan Andrea Barbieri Manju L. Prasad 《Diagnostic Histopathology》2021,27(6):263-271
Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid malignancy with high mortality rate. This malignancy arises in thyroid follicular cells either denovo or with an associated differentiated thyroid carcinoma component. Clinically, it usually presents as a rapidly enlarging mass, pain and locally compressive symptoms. Histopathologic variability and heterogeneity often pose diagnostic challenges, especially in scant and paucicellular specimens. This article describes the clinical, histopathologic and molecular features of ATC and also addresses the associated diagnostic limitations and challenges. 相似文献
3.
Rajiv V. Dave Baek Kim Alona Courtney Rachel OConnell Tim Rattay Vicky P. Taxiarchi Jamie J. Kirkham Elizabeth M. Camacho Patricia Fairbrother Nisha Sharma Christopher W. J. Cartlidge Kieran Horgan Stuart A. McIntosh Daniel R. Leff Raghavan Vidya Shelley Potter Chris Holcombe Ellen Copson Charlotte E. Coles Ramsey I. Cutress Ashu Gandhi Cliona C. Kirwan 《British journal of cancer》2021,124(11):1785
Background The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions.Methods This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting.Findings Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey.Conclusions The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.Subject terms: Breast cancer, Surgical oncology, Health care economics, Quality of life, Health policy 相似文献
4.
5.
6.
7.
8.
Uday Yanamandra Prateek Deo Kamal Kant Sahu Ram Vasudevan Nampoothiri Nalini Gupta Anusree Prabhakaran Deb Prasad Dhibhar Alka Khadwal Gaurav Prakash Man Upadesh Singh Sachdeva Deepesh Lad Neelam Varma Subhash Varma Pankaj Malhotra 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):183-189.e1
Background
Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting.Patients and Methods
In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE. The patients with MPE were analyzed for their clinical profile, diagnosis, treatment, and outcomes.Results
Of these 415 patients, 11 (2.65%) patients had MPE. The median age of the study population was 50 years with male preponderance. The majority of these patients had immunoglobin (Ig)G Kappa disease. All patients had higher than International Staging System stage I disease. MPE was a presenting feature at MM diagnosis in 45.45% (n = 5) of the patients, whereas the rest developed MPE during follow-up. MPE presented predominantly (81.8%) as a unilateral effusion. Concurrent extramedullary involvement at other site was seen in 45.45% (n = 5), with 3 (27%) patients having concurrent myelomatous ascites. Six of these were managed aggressively, whereas 5 patients opted for palliation. The outcomes were dismal (90.9% mortality), with a median survival of 2.47 months.Conclusion
MPE is a rare entity, and positive outcomes of therapy remain low with dismal prognosis. 相似文献9.
Pinki K. Prasad Priya Mahajan Douglas S. Hawkins Sogol Mostoufi‐Moab Rajkumar Venkatramani 《Pediatric blood & cancer》2020,67(6)
Differentiated thyroid cancer (DTC) is the most common childhood thyroid malignancy. The standard of care for pediatric DTC is total thyroidectomy followed by radioactive iodine (RAI) treatment when indicated. Molecular changes and potential therapeutic targets have been recently described in pediatric thyroid cancer. Pediatric oncologists are increasingly involved in the evaluation of thyroid nodules in childhood cancer survivors and in the management of advanced thyroid cancer. In 2015, the American Thyroid Association published management guidelines for children with DTC. We provide an overview of the current standard of care and highlight available targeted therapies for progressive or RAI refractory DTC. 相似文献